Cisplatin SR is under clinical development by Eleison Pharmaceuticals and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cisplatin SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cisplatin SR overview
Cisplatin (inhaled lipid-complexed cisplatin (ILC)) is under development for the treatment of pediatric osteosarcoma and non-small cell lung cancer. It is administered through the inhalational route. It is a nano scale lipid-based complex sustained-release formulation of cisplatin. It acts by targeting DNA synthesis. The drug complex is based on sustained release lipid inhalation targeting (SLIT) technology. It was also under development for the treatment of ovarian cancer.
Eleison Pharmaceuticals overview
Eleison Pharmaceuticals is a drug development company that acquires, develops, and commercializes clinical stage drug candidates for orphan cancers. The company’s pipeline products include glufosfamide and inhaled lipid-complexed cisplatin. Its glufosfamide is an analog of chemotherapeutic agent for treatment of metabolically active tumors and hypoxic tumor regions. Eleison Pharmaceuticals’ inhaled lipid-complexed cisplatin is a sustained release formulation of cisplatin in a nanoscale lipid based complex used for pediatric osteosarcoma – bone cancer. The company provides clinical trials for pancreatic cancer and osteosarcoma. Eleison Pharmaceuticals is headquartered in Princeton, New Jersey, the US.
For a complete picture of Cisplatin SR’s drug-specific PTSR and LoA scores, buy the report here.